HC Wainwright Issues Positive Forecast for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at HC Wainwright increased their Q2 2025 earnings per share estimates for Eton Pharmaceuticals in a research report issued on Monday, January 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.08 for the quarter, up from their previous forecast of $0.07. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2025 earnings at $0.38 EPS and FY2026 earnings at $0.84 EPS.

Separately, Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday.

Eton Pharmaceuticals Stock Performance

Shares of ETON stock opened at $12.01 on Thursday. The firm has a fifty day moving average of $11.64 and a 200-day moving average of $7.35. Eton Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $15.00. The stock has a market cap of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Thompson Siegel & Walmsley LLC bought a new position in Eton Pharmaceuticals during the 2nd quarter valued at about $420,000. Renaissance Technologies LLC raised its stake in shares of Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after acquiring an additional 41,469 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth approximately $3,095,000. Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $362,000. Finally, Aristides Capital LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth approximately $658,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.